Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
ARTV Announces Oral Presentation of AlloNK Data at Sjögren’s Symposium. Artiva Biotherapeutics will give an oral presentation of its AlloNK® clinical data at the 17th International Symposium on Sjögren’s Disease. The talk focuses on early results from a study in patients with this autoimmune disorder. The data could influence how investors view the company’s therapeutic pipeline. The presentation is a milestone before any formal publication or regulatory filing.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
BOLD trades near support amid sector news. Recent headlines focus on Beam Therapeutics and Callio Therapeutics rather than direct developments for Boundless Bio. The stock is currently trading near its identified support level, with technical indicators showing a breakdown signal. Analysts maintain a single price target of $4.00, which sits above the current trading range.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Acrivon Therapeutics noted among health‑care stocks moving in after‑market. Acrivon Therapeutics (ACRV) was included in a Benzinga roundup of twelve health‑care stocks that showed price movement during Wednesday’s after‑market session. The mention signals recent trading activity after regular hours. The stock is currently near its 52‑week low and its RSI is below 40, suggesting limited momentum.
Transaction History
| ZBIO | ▼ Sell | Other | 420,271 | — | 9/16/2024 | View on chart |
| ZBIO | ▼ Sell | Other | 200,718 | — | 9/16/2024 | View on chart |
| ZBIO | ▼ Sell | Other | 180,635 | — | 9/16/2024 | View on chart |
| ARTV | ▼ Sell | Other | 145,089 | — | 7/22/2024 | View on chart |
| ARTV | ▼ Sell | Other | 49,019 | $500K | 7/22/2024 | View on chart |
| BOLD | ▼ Sell | Other | 189,933 | — | 4/2/2024 | View on chart |
| BOLD | ▼ Sell | Other | 366,300 | — | 4/2/2024 | View on chart |
| ACRV | ▼ Sell | Other | 888,130 | — | 11/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ZBIO releases Phase 3 Obexelimab data, plans MS trial presentations
The company released new Phase 3 results for its Obexelimab program in IgG4‑related disease, which were presented at a recent international symposium. The data release coincided with a 5.1% share decline. Zenas also announced upcoming virtual presentations of Orelabrutinib data for multiple sclerosis at MSToronto2026 and a broader R&D webcast. Analyst HC Wainwright kept its $44 price target, reinforcing its view on the stock.
ZBIO releases Phase 3 Obexelimab data, plans MS trial presentations. The company released new Phase 3 results for its Obexelimab program in IgG4‑related disease, which were presented at a recent international symposium. The data release coincided with a 5.1% share decline. Zenas also announced upcoming virtual presentations of Orelabrutinib data for multiple sclerosis at MSToronto2026 and a broader R&D webcast. Analyst HC Wainwright kept its $44 price target, reinforcing its view on the stock.